Litcius/Paper detail

<i>TERT</i> promoter mutations in primary and secondary WHO grade III meningioma

Andrea Daniela Maier, Adam Stenman, Fredrika Svahn, Christian Mirian, Jir̂í Bártek, Marianne Juhler, Jan Zedenius, Helle Broholm, Tiit Mathiesen

2020Brain Pathology41 citationsDOIOpen Access PDF

Abstract

Abstract Purpose: TERT promoter mutation ( TERT p Mut ) has a strong association to recurrence and has been suggested to act as a driver mutation for malignant transformation of WHO grade I and II meningiomas. TERT p Mut has been investigated in selected high‐grade meningioma samples. The existence of TERT p Mut across recurrent tumors in a population‐based cohort needs to be investigated in order to identify when TERT p Mut emerges across recurrent samples and to validate prognostic impact among WHO grade III tumors. Methods: We gathered material from a consecutive single‐center cohort of 40 patients with malignant meningioma (WHO grade III) treated between 2000 and 2018, including specimens from primary and secondary malignant meningiomas with the corresponding earlier benign specimens and later malignant recurrences. In total 107 tumor samples were studied by Sanger sequencing for TERT promoter mutational status. Results: Seven of 40 patients (17.5%) harbored TERT p Mut thus validating the incidence of TERT p Mut in previous non‐population‐based cohorts. In 6/7 patients, the TERT p Mut was present at initial surgery (WHO grade I–III) while in one patient the TERT p Mut was found de novo when the meningioma became malignant. The incidences were 2/1.000.000/year for TERT p Mut WHO grade III meningioma and 8/1.000.000/year for TERT p wt WHO grade III meningioma in our catchment area. We found a 1.7 times higher recurrence rate (CI 95% 0.65–4.44) and a 2.5 higher mortality rate per 10 person‐years (CI 95% 1.01–6.19) for TERT p Mut compared to TERT p wt . Conclusion: TERT p Mut can occur independently of malignant progression in meningioma and was most often present from the first tumor sample across recurring tumors. TERT p Mut in WHO grade III may represent a marker of an aggressive subset of tumors.

Topics & Concepts

MeningiomaPrimary (astronomy)Cancer researchMutationMedicineGeneticsBiologyGenePathologyPhysicsAstronomyMeningioma and schwannoma managementPituitary Gland Disorders and TreatmentsNeurofibromatosis and Schwannoma Cases
<i>TERT</i> promoter mutations in primary and secondary WHO grade III meningioma | Litcius